Posted by Michael Wonder on 25 Mar 2025
Sungen Biomedical's world first new drug SGC001 monoclonal antibody receives FDA fast track approval
24 March 2025 - On 17 March 2025, US time, the world's first acute myocardial infarction antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech—received fast track Designation from the US FDA.
Currently, SGC001 is under clinical research for patients with acute myocardial infarction.
